Argenx has announced that the US Food and Drug Administration has accepted for priority review a supplemental biologics ...

AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving ...

On January 13, 2026, argenx SE announced that the U.S. Food and Drug Administration accepted for priority review its supplemental Biologics License Application for intravenous VYVGART (efgartigimod ...

Argenx (ARGX) stock gains as the FDA grants priority review to expand use of the company's blockbuster drug Vyvgart in myasthenia gravis. Read more here.

New sBLA for efgartigimod alfa-fcab aims to expand treatment for seronegative gMG patients who currently have limited medical options.

Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter ...

According to DelveInsight’s latest analysis, Nipocalimab is expected to capture meaningful market share across both prevalent ...

Investing.com -- Shares in Argenx (NASDAQ:ARGX) climbed 3.5% on Tuesday after the U.S. Food and Drug Administration accepted for priority review a supplemental biologics license application for the ...

A joint study by Tel Aviv University and the University of Haifa set out to solve a scientific mystery: how a soft coral is ...

Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19 ...